Printer Friendly

Alnylam, Arrowhead strike joint licensing contract.

M2 PHARMA-January 6, 2012-Alnylam, Arrowhead strike joint licensing contract(C)2012 M2 COMMUNICATIONS

6 January 2012 - US RNAi therapeutics specialist Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) and nanomedicine company Arrowhead Research Corp (NASDAQ:ARWR) said on Thursday they have sealed a collaboration and joint licensing deal.

Under the agreement, Arrowhead obtains a licence from Alnylam to develop an RNAi therapeutic toward hepatitis B virus (HBV). Alnylam is eligible to receive from Arrowhead milestone payments and royalties on sales of product emerging from the licence.

Further, Alnylam has gained a licence from Arrowhead to utilise the latter's Dynamic Polyconjugate (DPC) delivery technology for an RNAi therapeutic product. Alnylam expects to deploy this technology for an undisclosed target in its "Alnylam 5x15" pipeline which is focused on genetically defined targets and diseases. Arrowhead is eligible to receive from Alnylam milestone payments and royalties on sales of product resulting from the licence.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 6, 2012
Previous Article:Ironwood, Bionomics partner on anti-anxiety treatment.
Next Article:Sycamore purchases US Trunk Health Products.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters